Selected research
Industry Research
Pets Parasiticide Medicines Industry Research Report 2026
Market perspective
The global Pets Parasiticide Medicines market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Pets Parasiticide Medicines market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Pets Parasiticide Medicines market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Pets Parasiticide Medicines market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Pets Parasiticide Medicines include Bimeda Animal Health, Boehringer Ingelheim, Ceva Sante Animale, Elanco, Vetoquinol, Virbac, Zoetis, Bayer and Merck. among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Pets Parasiticide Medicines market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Pets Parasiticide Medicines.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Pets Parasiticide Medicines Market by Company
Bimeda Animal Health
Boehringer Ingelheim
Ceva Sante Animale
Elanco
Vetoquinol
Virbac
Zoetis
Bayer
Merck
Pets Parasiticide Medicines Segment by Type
In Vitro Parasiticide Medicines
In Vivo Parasiticide Medicines
Pets Parasiticide Medicines Segment by Application
Cats
Equine
Dogs
Others
Pets Parasiticide Medicines Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pets Parasiticide Medicines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Pets Parasiticide Medicines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pets Parasiticide Medicines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Pets Parasiticide Medicines companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- In Vitro Parasiticide Medicines
- In Vivo Parasiticide Medicines
Applications
- Cats
- Equine
- Dogs
- Others
Companies covered
- Bimeda Animal Health
- Boehringer Ingelheim
- Ceva Sante Animale
- Elanco
- Vetoquinol
- Virbac
- Zoetis
- Bayer
- Merck
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Pets Parasiticide Medicines by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 In Vitro Parasiticide Medicines
- 2.2.3 In Vivo Parasiticide Medicines
- 2.3 Pets Parasiticide Medicines by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Cats
- 2.3.3 Equine
- 2.3.4 Dogs
- 2.3.5 Others
- 2.4 Assumptions and Limitations
3 Pets Parasiticide Medicines Breakdown Data by Type
- 3.1 Global Pets Parasiticide Medicines Historic Market Size by Type (2021-2026)
- 3.2 Global Pets Parasiticide Medicines Forecasted Market Size by Type (2027-2032)
4 Pets Parasiticide Medicines Breakdown Data by Application
- 4.1 Global Pets Parasiticide Medicines Historic Market Size by Application (2021-2026)
- 4.2 Global Pets Parasiticide Medicines Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Pets Parasiticide Medicines Market Perspective (2021-2032)
- 5.2 Global Pets Parasiticide Medicines Growth Trends by Region
- 5.2.1 Global Pets Parasiticide Medicines Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Pets Parasiticide Medicines Historic Market Size by Region (2021-2026)
- 5.2.3 Pets Parasiticide Medicines Forecasted Market Size by Region (2027-2032)
- 5.3 Pets Parasiticide Medicines Market Dynamics
- 5.3.1 Pets Parasiticide Medicines Industry Trends
- 5.3.2 Pets Parasiticide Medicines Market Drivers
- 5.3.3 Pets Parasiticide Medicines Market Challenges
- 5.3.4 Pets Parasiticide Medicines Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Pets Parasiticide Medicines Players by Revenue
- 6.1.1 Global Top Pets Parasiticide Medicines Players by Revenue (2021-2026)
- 6.1.2 Global Pets Parasiticide Medicines Revenue Market Share by Players (2021-2026)
- 6.2 Global Pets Parasiticide Medicines Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Pets Parasiticide Medicines Head Office and Area Served
- 6.4 Global Pets Parasiticide Medicines Players, Product Type & Application
- 6.5 Global Pets Parasiticide Medicines Manufacturers Established Date
- 6.6 Global Pets Parasiticide Medicines Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Pets Parasiticide Medicines Market Size (2021-2032)
- 7.2 North America Pets Parasiticide Medicines Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Pets Parasiticide Medicines Market Size by Country (2021-2026)
- 7.4 North America Pets Parasiticide Medicines Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Pets Parasiticide Medicines Market Size (2021-2032)
- 8.2 Europe Pets Parasiticide Medicines Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Pets Parasiticide Medicines Market Size by Country (2021-2026)
- 8.4 Europe Pets Parasiticide Medicines Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Pets Parasiticide Medicines Market Size (2021-2032)
- 9.2 Asia-Pacific Pets Parasiticide Medicines Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Pets Parasiticide Medicines Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Pets Parasiticide Medicines Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Pets Parasiticide Medicines Market Size (2021-2032)
- 10.2 South America Pets Parasiticide Medicines Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Pets Parasiticide Medicines Market Size by Country (2021-2026)
- 10.4 South America Pets Parasiticide Medicines Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Pets Parasiticide Medicines Market Size (2021-2032)
- 11.2 Middle East & Africa Pets Parasiticide Medicines Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Pets Parasiticide Medicines Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Pets Parasiticide Medicines Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Bimeda Animal Health
- 12.1.1 Bimeda Animal Health Company Information
- 12.1.2 Bimeda Animal Health Business Overview
- 12.1.3 Bimeda Animal Health Revenue in Pets Parasiticide Medicines Business (2021-2026)
- 12.1.4 Bimeda Animal Health Pets Parasiticide Medicines Product Portfolio
- 12.1.5 Bimeda Animal Health Recent Developments
- 12.2 Boehringer Ingelheim
- 12.2.1 Boehringer Ingelheim Company Information
- 12.2.2 Boehringer Ingelheim Business Overview
- 12.2.3 Boehringer Ingelheim Revenue in Pets Parasiticide Medicines Business (2021-2026)
- 12.2.4 Boehringer Ingelheim Pets Parasiticide Medicines Product Portfolio
- 12.2.5 Boehringer Ingelheim Recent Developments
- 12.3 Ceva Sante Animale
- 12.3.1 Ceva Sante Animale Company Information
- 12.3.2 Ceva Sante Animale Business Overview
- 12.3.3 Ceva Sante Animale Revenue in Pets Parasiticide Medicines Business (2021-2026)
- 12.3.4 Ceva Sante Animale Pets Parasiticide Medicines Product Portfolio
- 12.3.5 Ceva Sante Animale Recent Developments
- 12.4 Elanco
- 12.4.1 Elanco Company Information
- 12.4.2 Elanco Business Overview
- 12.4.3 Elanco Revenue in Pets Parasiticide Medicines Business (2021-2026)
- 12.4.4 Elanco Pets Parasiticide Medicines Product Portfolio
- 12.4.5 Elanco Recent Developments
- 12.5 Vetoquinol
- 12.5.1 Vetoquinol Company Information
- 12.5.2 Vetoquinol Business Overview
- 12.5.3 Vetoquinol Revenue in Pets Parasiticide Medicines Business (2021-2026)
- 12.5.4 Vetoquinol Pets Parasiticide Medicines Product Portfolio
- 12.5.5 Vetoquinol Recent Developments
- 12.6 Virbac
- 12.6.1 Virbac Company Information
- 12.6.2 Virbac Business Overview
- 12.6.3 Virbac Revenue in Pets Parasiticide Medicines Business (2021-2026)
- 12.6.4 Virbac Pets Parasiticide Medicines Product Portfolio
- 12.6.5 Virbac Recent Developments
- 12.7 Zoetis
- 12.7.1 Zoetis Company Information
- 12.7.2 Zoetis Business Overview
- 12.7.3 Zoetis Revenue in Pets Parasiticide Medicines Business (2021-2026)
- 12.7.4 Zoetis Pets Parasiticide Medicines Product Portfolio
- 12.7.5 Zoetis Recent Developments
- 12.8 Bayer
- 12.8.1 Bayer Company Information
- 12.8.2 Bayer Business Overview
- 12.8.3 Bayer Revenue in Pets Parasiticide Medicines Business (2021-2026)
- 12.8.4 Bayer Pets Parasiticide Medicines Product Portfolio
- 12.8.5 Bayer Recent Developments
- 12.9 Merck
- 12.9.1 Merck Company Information
- 12.9.2 Merck Business Overview
- 12.9.3 Merck Revenue in Pets Parasiticide Medicines Business (2021-2026)
- 12.9.4 Merck Pets Parasiticide Medicines Product Portfolio
- 12.9.5 Merck Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst